A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and evaluate the safety and tolerability of open-label
brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult
subjects with bipolar I disorder. All participants received a starting dose of brexpiprazole.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.